Diabetes, obesity & metabolism

Use of Glucagon-Like Peptide-1 Drugs and Their Link to Risk of Mental Health Disorders

Updated

Abstract

A total of 133,378 participants across 86 trials showed no significant difference in psychiatric disorder incidence between GLP-1 receptor agonists and controls.

  • The risk of psychiatric disorders was not significantly different between the GLP-1 receptor agonists group and the control group (RR, 0.96).
  • No significant associations were found for specific psychiatric conditions, including depression, suicide, anxiety, and schizophrenia.
  • Meta-regression analyses indicated that changes in blood glucose levels, weight, or body mass index did not affect the risk of psychiatric disorders.
  • The study did not observe significant differences based on drug type, treatment duration, or baseline psychiatric conditions.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free